{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:48:12Z","timestamp":1790819292219,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s40264-019-00884-5","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T07:03:07Z","timestamp":1573542187000},"page":"211-221","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Prenatal Exposure to Macrolides and Risk of Congenital Malformations: A Meta-Analysis"],"prefix":"10.1007","volume":"43","author":[{"given":"Narmeen","family":"Mallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid Reza","family":"Tohidinik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahyar","family":"Etminan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"Figueiras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0739-2241","authenticated-orcid":false,"given":"Bahi","family":"Takkouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,12]]},"reference":[{"key":"884_CR1","unstructured":"World Health Organization. Congenital anomalies. World Health Organization. 2016. http:\/\/www.who.int\/mediacentre\/factsheets\/fs370\/en\/. Accessed 19 Feb 2019."},{"key":"884_CR2","unstructured":"Centers for Disease Control and Prevention. Birth Defects 2018. https:\/\/www.cdc.gov\/ncbddd\/birthdefects\/facts.html. Accessed 19 Feb 2019."},{"issue":"Suppl 1","key":"884_CR3","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/tera.90002","volume":"66","author":"J Petrini","year":"2002","unstructured":"Petrini J, Damus K, Russell R, Poschman K, Davidoff MJ, Mattison D. Contribution of birth defects to infant mortality in the United States. Teratology. 2002;66(Suppl 1):S3\u20136. https:\/\/doi.org\/10.1002\/tera.90002.","journal-title":"Teratology."},{"key":"884_CR4","unstructured":"Kochanek KD, Murphy SL, Xu JQ, Arias E. Mortality in the United States, 2016. NCHS Data Brief. 2017. Report No.: 293."},{"key":"884_CR5","unstructured":"Janz T, Navaneelan T, Pearson C. Deaths from congenital anomalies in Canada, 1974 to 2012. Health at a Glance. Statistics Canada. 2016. Catalogue No.: 82-624-X."},{"key":"884_CR6","unstructured":"Christianson A, Howson CP, Modell B. Global report on birth defects. The hidden toll of dying and disabled children. White Plains (NY): March of Dimes Birth Defects Foundation. 2006. https:\/\/www.marchofdimes.org\/global-report-on-birth-defects-the-hidden-toll-of-dying-and-disabled-children-full-report.pdf. Accessed 02 Apr 2019."},{"issue":"3","key":"884_CR7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/ajmg.c.30313","volume":"157C","author":"MP Adam","year":"2011","unstructured":"Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet. 2011;157C(3):175\u201382. https:\/\/doi.org\/10.1002\/ajmg.c.30313.","journal-title":"Am J Med Genet C Semin Med Genet."},{"issue":"11","key":"884_CR8","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/phar.1649","volume":"35","author":"PB Bookstaver","year":"2015","unstructured":"Bookstaver PB, Bland CM, Griffin B, Stover KR, Eiland LS, McLaughlin M. A review of antibiotic use in pregnancy. Pharmacotherapy. 2015;35(11):1052\u201362. https:\/\/doi.org\/10.1002\/phar.1649.","journal-title":"Pharmacotherapy."},{"issue":"11","key":"884_CR9","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1001\/archpediatrics.2009.188","volume":"163","author":"KS Crider","year":"2009","unstructured":"Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medication use during pregnancy and risk of birth defects: national birth defects prevention study. Arch Pediatr Adolesc Med. 2009;163(11):978\u201385. https:\/\/doi.org\/10.1001\/archpediatrics.2009.188.","journal-title":"Arch Pediatr Adolesc Med."},{"issue":"sup 1","key":"884_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/pds.3831","volume":"25","author":"R Brauer","year":"2016","unstructured":"Brauer R, Ruig\u00f3mez A, Downey G, Bate A, Rodriguez LAG, Huerta C, et al. Prevalence of antibiotic use: a comparison across various European health care data sources. Pharmacoepidemiol Drug Saf. 2016;25(sup 1):11\u201320. https:\/\/doi.org\/10.1002\/pds.3831.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"884_CR11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ajog.2012.12.023","volume":"208","author":"KJ Lin","year":"2013","unstructured":"Lin KJ, Mitchell AA, Yau WP, Louik C, Hernandez-Diaz S. Safety of macrolides during pregnancy. Am J Obstet Gynecol. 2013;208(3):221. https:\/\/doi.org\/10.1016\/j.ajog.2012.12.023.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"884_CR12","first-page":"e460","volume":"19","author":"F Santos","year":"2012","unstructured":"Santos F, Sheehy O, Perreault S, Ferreira E, Berard A. Trends in anti-infective drugs use in pregnancy. J Popul Ther Clin Pharmacol. 2012;19(3):e460\u20135.","journal-title":"J Popul Ther Clin Pharmacol."},{"issue":"2","key":"884_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.reprotox.2005.01.010","volume":"20","author":"BA Kallen","year":"2005","unstructured":"Kallen BA, Otterblad Olausson P, Danielsson BR. Is erythromycin therapy teratogenic in humans? Reprod Toxicol. 2005;20(2):209\u201314. https:\/\/doi.org\/10.1016\/j.reprotox.2005.01.010.","journal-title":"Reprod Toxicol."},{"key":"884_CR14","doi-asserted-by":"publisher","first-page":"g1908","DOI":"10.1136\/bmj.g1908","volume":"348","author":"M Lund","year":"2014","unstructured":"Lund M, Pasternak B, Davidsen RB, Feenstra B, Krogh C, Diaz LJ, et al. Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort study. BMJ. 2014;348:g1908. https:\/\/doi.org\/10.1136\/bmj.g1908.","journal-title":"BMJ."},{"issue":"7","key":"884_CR15","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1128\/AAC.01691-12","volume":"57","author":"AB Dinur","year":"2013","unstructured":"Dinur AB, Koren G, Matok I, Wiznitzer A, Uziel E, Gorodischer R, et al. Fetal safety of macrolides. Antimicrob Agents Chemother. 2013;57(7):3307\u201311. https:\/\/doi.org\/10.1128\/AAC.01691-12.","journal-title":"Antimicrob Agents Chemother."},{"issue":"1","key":"884_CR16","doi-asserted-by":"publisher","first-page":"e53327","DOI":"10.1371\/journal.pone.0053327","volume":"8","author":"JT Andersen","year":"2013","unstructured":"Andersen JT, Petersen M, Jimenez-Solem E, Broedbaek K, Andersen NL, Torp-Pedersen C, et al. Clarithromycin in early pregnancy and the risk of miscarriage and malformation: a register based nationwide cohort study. PLoS One. 2013;8(1):e53327. https:\/\/doi.org\/10.1371\/journal.pone.0053327.","journal-title":"PLoS One."},{"issue":"2","key":"884_CR17","doi-asserted-by":"publisher","first-page":"e0212212","DOI":"10.1371\/journal.pone.0212212","volume":"14","author":"H Fan","year":"2019","unstructured":"Fan H, Li L, Wijlaars L, Gilbert RE. Associations between use of macrolide antibiotics during pregnancy and adverse child outcomes: a systematic review and meta-analysis. PLoS One. 2019;14(2):e0212212. https:\/\/doi.org\/10.1371\/journal.pone.0212212.","journal-title":"PLoS One."},{"key":"884_CR18","unstructured":"Prospero International Prospective Register of Systematic Reviews. 2017. https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=55131."},{"key":"884_CR19","unstructured":"Wells GA, Shea B, O\u2019Connell D, et al. The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 19 Feb 2019."},{"key":"884_CR20","first-page":"61","volume-title":"Measure of effect and measures of association. Modern epidemiology","author":"KJ Rothman","year":"2008","unstructured":"Rothman KJ, Greenland S, Lash TL. Measure of effect and measures of association. Modern epidemiology. 3rd ed. Philadelphia: Lippincott, Williams and Wilkins; 2008. p. 61.","edition":"3"},{"issue":"2","key":"884_CR21","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/oxfordjournals.aje.a009981","volume":"150","author":"B Takkouche","year":"1999","unstructured":"Takkouche B, Cadarso-Su\u00e1rez C, Spiegelman D. Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis. Am J Epidemiol. 1999;150(2):206\u201315.","journal-title":"Am J Epidemiol."},{"issue":"3","key":"884_CR22","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s00228-013-1624-3","volume":"70","author":"B Kallen","year":"2014","unstructured":"Kallen B, Danielsson BR. Fetal safety of erythromycin. An update of Swedish data. Eur J Clin Pharmacol. 2014;70(3):355\u201360. https:\/\/doi.org\/10.1007\/s00228-013-1624-3.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"884_CR23","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1067\/mpd.2001.117577","volume":"139","author":"BE Mahon","year":"2001","unstructured":"Mahon BE, Rosenman MB, Kleiman MB. Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis. J Pediatr. 2001;139(3):380\u20134. https:\/\/doi.org\/10.1067\/mpd.2001.117577.","journal-title":"J Pediatr"},{"key":"884_CR24","unstructured":"Wolfgang P, Schloemp S, Sterzik K, Stoz F, editors. Does roxithromycin affect embryo development? 33rd Annual Conference of the European Teratology Society; 3\u20137 Sep, 2005; Haarlem, The Netherlands: Reproductive Toxicology."},{"issue":"8","key":"884_CR25","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/j.clinthera.2017.05.037","volume":"39","author":"T L\u00ea Nguy\u00ean","year":"2017","unstructured":"L\u00ea Nguy\u00ean T, Araujo M, Hurault-Delarue C, Lacroix I, Damase-Michel C, Sommet A. Teratogenic risk of macrolides during the first trimester of pregnancy: a study with two complementary approaches within the EFEMERIS database. Clin Ther. 2017;39(8):e11\u20132.","journal-title":"Clin Ther"},{"issue":"7109","key":"884_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ."},{"key":"884_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0169-2607(00)00087-0","volume":"64","author":"J Costa-Bouzas","year":"2001","unstructured":"Costa-Bouzas J, Takkouche B, Cadarso-Su\u00e1rez C, Spiegelman D. HEpiMA: software for the identification of heterogeneity in meta-analysis. Comput Methods Programs Biomed. 2001;64:101\u20137.","journal-title":"Comput Methods Programs Biomed"},{"issue":"7","key":"884_CR28","doi-asserted-by":"publisher","first-page":"589","DOI":"10.2165\/11630920-000000000-00000","volume":"35","author":"B Bar-Oz","year":"2012","unstructured":"Bar-Oz B, Weber-Schoendorfer C, Berlin M, Clementi M, Di Gianantonio E, de Vries L, et al. The outcomes of pregnancy in women exposed to the new macrolides in the first trimester: a prospective, multicentre, observational study. Drug Saf. 2012;35(7):589\u201398. https:\/\/doi.org\/10.2165\/11630920-000000000-00000.","journal-title":"Drug Saf."},{"issue":"6","key":"884_CR29","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/j.1365-2125.2012.04286.x","volume":"74","author":"M Romoren","year":"2012","unstructured":"Romoren M, Lindbaek M, Nordeng H. Pregnancy outcome after gestational exposure to erythromycin\u2014a population-based register study from Norway. Br J Clin Pharmacol. 2012;74(6):1053\u201362. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04286.x.","journal-title":"Br J Clin Pharmacol."},{"issue":"1","key":"884_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1365-3016.2008.00978.x","volume":"23","author":"WO Cooper","year":"2009","unstructured":"Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer SM, Gideon PS, et al. Antibiotics potentially used in response to bioterrorism and the risk of major congenital malformations. Paediatr Perinat Epidemiol. 2009;23(1):18\u201328. https:\/\/doi.org\/10.1111\/j.1365-3016.2008.00978.x.","journal-title":"Paediatr Perinat Epidemiol."},{"issue":"1","key":"884_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejogrb.2008.07.008","volume":"141","author":"B Bar-Oz","year":"2008","unstructured":"Bar-Oz B, Diav-Citrin O, Shechtman S, Tellem R, Arnon J, Francetic I, et al. Pregnancy outcome after gestational exposure to the new macrolides: a prospective multi-center observational study. Eur J Obstet Gynecol Reprod Biol. 2008;141(1):31\u20134. https:\/\/doi.org\/10.1016\/j.ejogrb.2008.07.008.","journal-title":"Eur J Obstet Gynecol Reprod Biol."},{"issue":"3","key":"884_CR32","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/14767050500439657","volume":"19","author":"JY Chun","year":"2006","unstructured":"Chun JY, Han JY, Ahn HK, Choi JS, Koong MK, Nava-Ocampo AA, et al. Fetal outcome following roxithromycin exposure in early pregnancy. J Matern Fetal Neonatal Med. 2006;19(3):189\u201392. https:\/\/doi.org\/10.1080\/14767050500439657.","journal-title":"J Matern Fetal Neonatal Med"},{"key":"884_CR33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1471-2393-6-18","volume":"6","author":"M Sarkar","year":"2006","unstructured":"Sarkar M, Woodland C, Koren G, Einarson AR. Pregnancy outcome following gestational exposure to azithromycin. BMC Pregnancy Childbirth. 2006;6:18. https:\/\/doi.org\/10.1186\/1471-2393-6-18.","journal-title":"BMC Pregnancy Childbirth"},{"issue":"9","key":"884_CR34","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1055\/s-2007-994053","volume":"15","author":"A Einarson","year":"1998","unstructured":"Einarson A, Phillips E, Mawji F, D\u2019Alimonte D, Schick B, Addis A, et al. A prospective controlled multicentre study of clarithromycin in pregnancy. Am J Perinatol. 1998;15(9):523\u20135. https:\/\/doi.org\/10.1055\/s-2007-994053.","journal-title":"Am J Perinatol."},{"issue":"7","key":"884_CR35","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1001\/archpedi.156.7.647","volume":"156","author":"WO Cooper","year":"2002","unstructured":"Cooper WO, Griffin MR, Arbogast P, Hickson GB, Gautam S, Ray WA. Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. Arch Pediatr Adolesc Med. 2002;156(7):647\u201350. https:\/\/doi.org\/10.1001\/archpedi.156.7.647.","journal-title":"Arch Pediatr Adolesc Med."},{"issue":"8","key":"884_CR36","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1111\/j.1471-0528.1998.tb10234.x","volume":"105","author":"LV Wilton","year":"1998","unstructured":"Wilton LV, Pearce GL, Martin RM, Mackay FJ, Mann RD. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol. 1998;105(8):882\u20139.","journal-title":"Br J Obstet Gynaecol."},{"issue":"11","key":"884_CR37","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1111\/bcp.13364","volume":"83","author":"FT Muanda","year":"2017","unstructured":"Muanda FT, Sheehy O, Berard A. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study. Br J Clin Pharmacol. 2017;83(11):2557\u201371. https:\/\/doi.org\/10.1111\/bcp.13364.","journal-title":"Br J Clin Pharmacol."},{"issue":"3","key":"884_CR38","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1080\/j.1600-0412.2000.079003234.x","volume":"79","author":"AE Czeizel","year":"2000","unstructured":"Czeizel AE, Rockenbauer M, Olsen J, Sorensen HT. A case\u2013control teratological study of spiramycin, roxithromycin, oleandomycin and josamycin. Acta Obstet Gynecol Scand. 2000;79(3):234\u20137.","journal-title":"Acta Obstet Gynecol Scand."},{"issue":"2","key":"884_CR39","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1067\/mob.2002.119718","volume":"186","author":"C Louik","year":"2002","unstructured":"Louik C, Werler MM, Mitchell AA. Erythromycin use during pregnancy in relation to pyloric stenosis. Am J Obstet Gynecol. 2002;186(2):288\u201390. https:\/\/doi.org\/10.1067\/mob.2002.119718.","journal-title":"Am J Obstet Gynecol."},{"issue":"6","key":"884_CR40","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/s0890-6238(99)00046-5","volume":"13","author":"AE Czeizel","year":"1999","unstructured":"Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. A population-based case\u2013control teratologic study of oral erythromycin treatment during pregnancy. Reprod Toxicol. 1999;13(6):531\u20136. https:\/\/doi.org\/10.1016\/s0890-6238(99)00046-5.","journal-title":"Reprod Toxicol"},{"issue":"1","key":"884_CR41","doi-asserted-by":"publisher","first-page":"33","DOI":"10.17772\/gp\/1896","volume":"86","author":"M Bulska","year":"2015","unstructured":"Bulska M, Szcze\u015bniak P, Pi\u0119ta-Doli\u0144ska A, Oszukowski P, Orszulak-Michalak D. The placental transfer of erythromycin in human pregnancies with group B streptococcal infection. Ginekol Pol. 2015;86(1):33\u20139.","journal-title":"Ginekol Pol."},{"issue":"9","key":"884_CR42","doi-asserted-by":"publisher","first-page":"787","DOI":"10.2174\/1381612013397744","volume":"7","author":"BR Danielsson","year":"2001","unstructured":"Danielsson BR, Skold AC, Azarbayjani F. Class III antiarrhythmics and phenytoin: teratogenicity due to embryonic cardiac dysrhythmia and reoxygenation damage. Curr Pharm Des. 2001;7(9):787\u2013802.","journal-title":"Curr Pharm Des."},{"issue":"6","key":"884_CR43","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1128\/AAC.00438-18","volume":"62","author":"E Gorelik","year":"2018","unstructured":"Gorelik E, Masarwa R, Perlman A, Rotshild V, Muszkat M, Matok I. Systematic review, meta-analysis, and network meta-analysis of the cardiovascular safety of macrolides. Antimicrob Agents Chemother. 2018;62(6):89. https:\/\/doi.org\/10.1128\/AAC.00438-18.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"884_CR44","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.2105\/AJPH.2014.302098","volume":"104","author":"MA Canfield","year":"2014","unstructured":"Canfield MA, Mai CT, Wang Y, O\u2019Halloran A, Marengo LK, Olney RS, et al. The association between race\/ethnicity and major birth defects in the United States, 1999\u20132007. Am J Public Health. 2014;104(9):e14\u201323. https:\/\/doi.org\/10.2105\/AJPH.2014.302098.","journal-title":"Am J Public Health."},{"key":"884_CR45","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1469-0691.2009.02725.x","volume":"15","author":"H Goossens","year":"2009","unstructured":"Goossens H. Antibiotic consumption and link to resistance. Clin Microbiol Infect. 2009;15:12\u20135. https:\/\/doi.org\/10.1111\/j.1469-0691.2009.02725.x.","journal-title":"Clin Microbiol Infect"},{"issue":"5 Pt 1","key":"884_CR46","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/s0029-7844(00)01019-x","volume":"96","author":"LM Hollier","year":"2000","unstructured":"Hollier LM, Leveno KJ, Kelly MA, MCIntire DD, Cunningham FG. Maternal age and malformations in singleton births. Obstet Gynecol. 2000;96(5 Pt 1):701\u20136. https:\/\/doi.org\/10.1016\/s0029-7844(00)01019-x.","journal-title":"Obstet Gynecol"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-019-00884-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-019-00884-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-019-00884-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T19:48:34Z","timestamp":1605037714000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-019-00884-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,12]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["884"],"URL":"https:\/\/doi.org\/10.1007\/s40264-019-00884-5","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,12]]},"assertion":[{"value":"12 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No specific funding for this work. Dr. Takkouche\u2019s and Dr. Figueiras\u2019 work is funded by a Grant from the Regional Ministry of Education, Universities and Vocational Training, Santiago de Compostela, Spain, ED431C 2018\/20.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding Source"}},{"value":"Narmeen Mallah, Hamid\u00a0Reza Tohidinik, Mahyar Etminan, Adolfo Figueiras, and Bahi Takkouche declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All data generated or analyzed during this study are included in this published article and its Supplementary Information File (Online Resource 1, see ESM).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Sharing"}}]}}